Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) announced its earnings results on Thursday. The company reported ($0.21) earnings per share (EPS) for the quarter, Zacks reports.
Eupraxia Pharmaceuticals Stock Performance
Shares of NASDAQ:EPRX traded down $0.11 during midday trading on Thursday, hitting $3.91. 5,147 shares of the company’s stock traded hands, compared to its average volume of 16,544. The company has a market cap of $139.38 million and a PE ratio of -5.43. The firm’s fifty day moving average price is $3.46 and its two-hundred day moving average price is $3.09. Eupraxia Pharmaceuticals has a twelve month low of $2.20 and a twelve month high of $4.48.
Wall Street Analyst Weigh In
Separately, Craig Hallum initiated coverage on shares of Eupraxia Pharmaceuticals in a research report on Friday, February 21st. They set a “buy” rating and a $12.00 target price on the stock.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
See Also
- Five stocks we like better than Eupraxia Pharmaceuticals
- Where to Find Earnings Call Transcripts
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- Comparing and Trading High PE Ratio Stocks
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- Most Volatile Stocks, What Investors Need to Know
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
